Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma
Status:
Withdrawn
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The purpose of his study is to evaluate the efficacy and safety of Sorafenib versus placebo
in subjects with locally advanced medullary thyroid cancer (MTC). The primary study objective
is to compare the Progression-free Survival (PFS) of the Sorafenib treatment group with the
placebo treatment group in patients with advanced MTC.